Condiciones de salud que Bifidobacterium longum puede ayudar a apoyar.
Bifidobacterium longum (including the strain formerly classified as B. infantis 35624) has demonstrated efficacy for IBS-related abdominal discomfort in RCTs. Meta-analyses confirm its benefits for key IBS symptoms including abdominal pain. NIH ODS cites evidence that B. longum-containing probiotics reduce IBS pain scores.
Multiple RCTs show B. longum strains reduce anxiety-related measures in humans. Strain NCC3001 reduced anxiety scores in IBS patients and correlated with reduced fearful stimulus reactions. Strain 1714 reduced self-reported anxiety in response to acute stress in healthy adults. The mechanism appears to involve the vagus nerve and gut-brain axis.
Clinical trials show select B. longum strains can modestly improve glycemic markers. A 12-week RCT found B. longum APC1472 significantly reduced fasting blood glucose in overweight/obese adults. A 2026 RCT of B. longum BL21 in type 2 diabetics on metformin showed a significant reduction in HbA1c. However, a meta-analysis of 6 RCTs found no overall significant effect of Bifidobacterium on fasting blood glucose.
Bifidobacterium longum IATA-ES1 has demonstrated in vitro capacity to degrade gliadin-derived peptides and reduce gliadin-induced inflammatory cytokines in CeD cell models. B. longum ATCC 15707 reduces IFN-γ and TNF-α and increases IL-10 in response to gliadin peptides in vitro. B. longum was included in the VSL#3 blend evaluated in a randomized controlled trial in celiac disease.
Bifidobacterium longum has been studied in children with allergic rhinitis and atopic dermatitis. A 2024 randomized, double-blind, placebo-controlled trial in children aged 6–19 found that a mixture of B. longum and Lactobacillus plantarum significantly improved nasal symptom scores and quality of life in perennial allergic rhinitis. Meta-analyses support its role in reducing eczema and wheezing in children, and mechanistic work shows it lowers Th2 cytokines and serum IgE.
Bifidobacterium longum is a key species in the infant and child gut and has been studied for its role in reducing harmful gut bacteria, improving microbiota balance, and decreasing diarrhea frequency in children. Ingestion of B. longum-fortified yogurt has been shown to reduce Enterobacteriaceae and C. perfringens while increasing beneficial microflora in children.
Bifidobacterium longum is a key gut probiotic with documented benefits for children's immune health. A 2025 RCT of B. longum subsp. infantis B8762 in 115 infants found supplementation reduced infection duration and lowered clinical visits for respiratory and gastrointestinal illness. B. longum supports IgA production and anti-inflammatory cytokine responses in the gut-lung immune axis.
B. longum CCFM1077 was tested in a 6-week double-blind RCT in 62 hyperlipidemic subjects for its lipid-lowering effects, with serum TC, LDL-C, TG, and HDL-C as endpoints. Bifidobacteria are proposed to reduce blood cholesterol by absorbing intestinal cholesterol for fecal excretion and by modulating bile acid metabolism.
B. longum has demonstrated anti-inflammatory effects in both clinical and preclinical settings, primarily through reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and modulation of intestinal barrier function. Clinical evidence is strongest in IBD-related inflammation, with animal and in vitro data supporting broader systemic inflammation reduction.
An RCT in 60 healthy older adults found B. longum BB68S improved total cognitive function scores significantly after 8 weeks. B. longum is the most detected Bifidobacterium species from newborns to centenarians. Preclinical data show B. longum reduces amyloid pathology in Alzheimer's disease mouse models, with mechanistic links to neuroinflammation and BDNF.
B. longum (particularly subspecies infantis) has been studied as an intervention for infant colic and functional gastrointestinal disorders. Observational pilot trial data show that B. longum KABP042 combined with Pediococcus pentosaceus KABP041 shows potential to treat pediatric functional gastrointestinal disorders including infant colic. B. infantis is well adapted to the infant gut and supports gut homeostasis relevant to colic.
Bifidobacterium longum BB536 has been specifically identified in clinical studies as beneficial for UC symptom management. It is among the most frequently studied Bifidobacterium strains for UC alongside L. rhamnosus GG. VSL#3 probiotic mixture containing B. longum showed benefit in pouchitis RCTs.
Bifidobacterium longum is a probiotic species included in multi-strain formulations with demonstrated constipation RCT efficacy. A 4-week RCT (n=94 adults with functional constipation) found a multi-strain blend containing B. longum UABl-14 produced faster normalization of stool frequency and consistency vs. placebo. Systematic reviews confirm the overall benefit of Bifidobacterium-containing probiotics for chronic constipation.
B. longum has been studied as an adjunctive therapy in inflammatory bowel disease including Crohn's disease. Clinical trials and a 2021 review in the Journal of Immunology Research summarize evidence that B. longum can reduce IBD symptoms and intestinal inflammation, with lower fecal B. longum abundance consistently found in IBD patients compared to healthy controls.
B. longum NCC3001 demonstrated significant improvement in depression scores in IBS patients in an RCT, associated with decreased emotional reactivity to fearful stimuli. Post-hoc analysis from a 6-week RCT in healthy adults found that reduced perceived stress correlated with reductions in depression scores. The gut-brain axis is the proposed mechanistic pathway.
Bifidobacterium longum has been specifically studied in RCTs for atopic dermatitis. A combination of B. longum CECT 7347 with other probiotic strains was shown to reduce SCORAD values and topical steroid use in moderate AD. It is among the most-studied Bifidobacterium species for AD.
Bifidobacterium longum is supported by evidence within the broader Bifidobacterium literature for antibiotic-associated and acute infectious diarrhea. It is included in Cochrane reviews and meta-analyses of probiotic interventions demonstrating reduced AAD incidence from 19% to 8% in children.
Bifidobacterium longum is a specific strain included in the VSL#3 probiotic formulation studied in 12-month RCTs in diverticular disease remission. Multi-strain formulations containing B. longum have been associated with maintained symptom relief in diverticular disease, and the broader evidence from a 2025 meta-analysis supports the role of Bifidobacterium-containing multi-strain probiotics in reducing diverticular disease pain and recurrence.
Bifidobacterium longum is one of the three most evidence-supported probiotic strains for atopic eczema, with multiple RCTs showing prevention in high-risk infants and SCORAD reduction in children with established AD. A randomized double-blind placebo-controlled trial demonstrated B. longum CECT 7347 in combination reduced SCORAD in pediatric AD.
Bifidobacterium longum has been studied in clinical trials for food allergy prevention and management. It is referenced in the ScienceDirect nutraceuticals review as a probiotic with documented benefits in allergic children. It modulates gut microbiota composition, promotes regulatory immune responses, and has been evaluated in combination probiotic formulations for atopic disease linked to food sensitization.
Bifidobacterium longum has been used in clinical RCTs demonstrating improvement in intestinal permeability and gut barrier function relevant to food sensitivity. An RCT in elderly subjects using B. longum in a multi-strain formula significantly improved permeability biomarkers, and perioperative supplementation with B. longum reduced post-surgical gut barrier disruption.
Bifidobacterium longum has demonstrated inhibitory effects against H. pylori in vitro and in vivo and is used in multi-strain probiotic formulations for H. pylori-associated gastritis treatment. It contributes to gastric mucosal immune modulation and reduction of gastric inflammation.
Bifidobacterium longum is among the best-studied probiotic species in the gut, demonstrating documented effects on gut microbiota composition, SCFA production, intestinal barrier function, and modulation of gut-brain axis signaling. It is effective in IBS, antibiotic-associated dysbiosis, and infant gut microbiome establishment.
Bifidobacterium longum, particularly strains 1714® and 35624®, has the strongest human clinical evidence among Bifidobacterium species for gut-brain axis effects. RCTs show strain 1714® reduces tension and improves memory in healthy volunteers, with measurable EEG and cortisol changes. It is the paradigmatic 'psychobiotic' strain.
B. longum is the predominant Bifidobacterium species detected across all human age groups including centenarians, with an 88.1% detection rate in a study spanning newborns to >100-year-olds. A preclinical model (C. elegans) showed B. longum BB68 extended lifespan by 28% via DAF-16 signaling. An RCT in healthy older adults showed B. longum BB68S improved cognitive function, supporting a role in healthy aging.
Bifidobacterium longum is identified as a histamine-degrading probiotic that does not produce histamine. Strain BB536 studied in combination with B. infantis 35624 (mixture called Lac-B) significantly suppressed allergic symptoms and decreased histamine levels, including suppression of histidine decarboxylase gene expression. It is recommended in HIT probiotic protocols.
Bifidobacterium longum 35624 (formerly B. infantis 35624) has the strongest meta-analytic evidence among Bifidobacterium species for IBS, confirmed in a 2025 systematic review of 32 RCTs. Multiple trials document significant improvements in abdominal pain, bloating, and bowel function. It is one of five probiotic strains with meta-analytic IBS efficacy in current systematic reviews alongside L. rhamnosus GG and L. plantarum 299v.
Bifidobacterium longum has one of the strongest clinical evidence bases among Bifidobacterium species in IBD. Synbiotic preparations combining B. longum with prebiotics have demonstrated significant improvement in endoscopic and histological scores in UC in randomized trials.
Bifidobacterium longum has been tested in multiple RCTs for lactose intolerance, including a randomized double-blind crossover study (n=23) where B. longum BB536 combined with Lactobacillus rhamnosus HN001 and vitamin B6 alleviated persistent GI symptoms in LI subjects on a lactose-free diet. B. longum also increases fecal β-galactosidase activity. A capsule trial (Jaagura et al., 2022) showed improved symptom scores and microbiota modulation.
Bifidobacterium longum is among the most studied Bifidobacterium species for intestinal barrier restoration. Multiple high-quality clinical studies demonstrate it restores intestinal barrier function and reduces intestinal permeability in IBS patients, overweight and obese adults, and colon cancer patients. A double-blind RCT in IBS patients found BB536 combined with L. rhamnosus HN001 reduced colonic permeability in subjects with elevated baseline values.
An RCT in 60 healthy older adults found B. longum BB68S (5×10¹⁰ CFU/day, 8 weeks) significantly improved immediate memory, delayed memory, attention, and visuospatial function as measured by the RBANS neuropsychological battery. Preclinical data in Alzheimer's disease mouse models also show B. longum BORI reduced amyloid pathology and improved memory.
Bifidobacterium longum has been included in oral probiotic formulations and evaluated for its ability to inhibit oral pathogens. In vitro studies demonstrate antimicrobial activity against S. mutans and periodontal pathogens. It is part of the broader evidence base for Bifidobacterium species modulating oral microbial ecology.
Bifidobacterium longum is one of the Bifidobacterium strains explicitly included in RCTs of probiotic supplementation for PCOS. These trials have shown improvements in metabolic, hormonal, and inflammatory parameters in PCOS women.
One of the most studied probiotic species for immune support and post-illness recovery. A patent specifically designed for long COVID recovery lists Bifidobacterium longum as a key component alongside other beneficial bacteria. It supports immune function through gut-associated lymphoid tissue modulation and reduces post-illness fatigue.
Bifidobacterium longum is a probiotic species used in perioperative synbiotic formulations with documented ability to reduce post-surgical infectious complications and modulate immune function. It is among the Bifidobacterium species included in ESPEN-recommended perioperative probiotic/synbiotic protocols for colorectal surgery patients.
Bifidobacterium longum is one of three specific probiotic species highlighted in a 2025 PMC systematic review (PMC12566607) as having clinical trial evidence for alleviating long-term COVID-19 symptoms. It supports gut barrier restoration and immune modulation impaired in post-viral states.
Bifidobacterium longum is a probiotic that supports postpartum gut microbiome restoration and maternal mood. It is one of the dominant Bifidobacterium species in breast milk, contributing to infant gut colonization. Evidence from perinatal probiotic trials shows B. longum supplementation reduces postpartum depression scores and gut permeability.
Bifidobacterium longum is a probiotic species studied in prenatal formulations for reducing gestational diabetes, improving maternal gut microbiome composition, and colonizing the neonatal gut with health-promoting bacteria. As a component of multi-strain probiotic supplements used in pregnancy RCTs, B. longum contributes to reductions in GDM risk and neonatal atopic disease seen in systematic reviews.
B. longum MM-2 improved rhinoconjunctivitis-specific quality of life in healthy individuals with self-reported seasonal allergies during allergy season. A Bifidobacterium mixture including B. longum BB536 significantly improved nasal allergy symptoms and quality of life in a placebo-controlled RCT in children with allergic rhinitis.
Bifidobacterium longum BB536 has been studied in randomized trials for seasonal allergic rhinitis, both as monotherapy and in combination probiotic mixtures. It was included in a combination trial in children with SAR and intermittent asthma showing symptomatic benefit, and is part of the 2016 meta-analysis evidence base of 22 RDBPCTs showing significant probiotic benefit for AR.
Bifidobacterium longum was specifically used as post-antibiotic SIBO treatment support in a clinical study protocol (Redondo-Cuevas), and is included in the SIBO probiotic evidence reviewed by the 2017 Zhong meta-analysis. It reduces intestinal permeability and supports microbiome rebalancing after SIBO eradication.
Two distinct RCTs demonstrate B. longum improves sleep quality. B. longum 1714 (8-week, double-blind RCT, n=89) significantly improved the PSQI sleep quality component and reduced daytime dysfunction due to sleepiness. B. longum NCC3001 (6-week RCT, n=45) also improved subjective sleep quality scores versus placebo.
B. longum NCC3001 significantly reduced perceived stress in a double-blind RCT of 45 healthy adults. B. longum 1714 reduced cortisol output in response to acute stress and altered brain-wave patterns associated with stress arousal. A combined probiotic (B. longum R0175 + L. helveticus R0052) reduced urinary free cortisol in a separate RCT.
Bifidobacterium longum is among the Bifidobacterium species with recognized roles in gut-urinary axis protection. It supports urinary flora indirectly by reducing the gut reservoir of uropathogens and modulating systemic immune responses relevant to UTI susceptibility. Cleveland Clinic includes it among Bifidobacterium species with documented relevance to urinary and vaginal tract health.
Bifidobacterium longum is listed among well-studied commercially available probiotics for BV and vaginitis treatment, and oral probiotic formulations including B. longum alongside vaginal lactobacilli have demonstrated vaginal microbiome restoration in clinical studies. It modulates mucosal immunity and has antimicrobial properties relevant to vaginal health.
Volver